For Ulcerative Colitis, Two First-In-Class Candidates and an Interleukin-23 Competition

February 01, 2023

A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.

Dampened Response to COVID-19 Vaccines in Rituxan-Treated Patients with MS May Improve with Extended Dosing Intervals

January 24, 2023

A study by Kaiser Permanente researchers found that the overall the risk of COVID-19-related hospitalization was low in vaccinated individuals with multiple sclerosis, regardless of whether participants had received Rituxan treatment. Still, the findings suggest that spacing out vaccination may offer added protection against COVID-19.